CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

AXA Group

Robert WALSH, Deputy CCO

The Evolving Financial Crime Regulatory Landscape

Robert WALSH

Robert WALSH

For many years financial crime regulations have mainly been a problem for banks and other financial institutions. Those days are over. Is your company at risk because your supply chain includes companies in western China? Do you have customers with operations that extend into sanctioned countries? Are you unwittingly in violation of new strict anti-bribery laws in France? Have you even heard about the UK Modern Slavery Act or the new EU equivalent?


All companies, whether manufacturers or service companies, now have need to deal with these complicated areas of regulation. What’s even harder is that most of these laws have extra-territorial application, meaning that if any part of your operations are in the regulating country then the regulator might assert that their law applies to all of your operations.


That’s the bad news. The good news is that because big banks have been at the bleeding edge of these laws, suffering penalties running into the billions of dollars, they have invested heavily in specialized technologies to prevent these problems. These tools are generally available and are rapidly improving in their effectiveness.


Underlying all of these laws is a regulatory insistence that companies really, really know who they are dealing with. Customers, suppliers, contractors, TPAs, intermediaries, JV partners, directors, employees - none of these parties can be on prohibited lists. So companies must have screening technology to check them against the lists. If any of these parties are companies, you must identify controlling shareholders and make sure those shareholders are not on restricted lists. This is a big job but it can be done: specialized data vendors have emerged that work in concert with these technologies.


Under emerging bribery laws, such as the French Sapin 2 law, companies must assess the corruption risk of the third parties they deal with. The good news is that screening technologies can be used for this purpose as well and, again, specialized data vendors are available, who offer “negative media” lists to help assess the background of counterparties. 


Perhaps the most significant international bribery law is the US Foreign Corrupt Practices Act, which adds a further layer of due diligence, which is whether your counterparty is a government entity or political/public official. All of this can be screened using these tools.


With respect to the supply chain laws, the essential ingredient is to try to determine whether companies in your supply chain are engaged in human rights abuses. This is not wholly solved by screening technology and services, but increasingly dubious suppliers are listed in the negative media screening services.


Unfortunately it doesn’t end there. There is an emerging expectation that, beyond ensuring your customers are not bad guys, you should ensure your customer’s customers are not bad guys (know your customer’s customer or KYCC). This expectation is particularly relevant to manufacturers with international clients. If the car parts your company makes end up in North Korea you may have a serious problem. Once again, new specialized data vendors coupled with customer screening technology can help solve this.


One more point. Apart from the regulatory reasons for engaging in these screening practices, increasingly there is pressure from other directions. If you are a public company, institutional investors now include ESG (Environmental, Social & Governance) factors in their investment decisions, including anti-bribery and supply chain compliance, and bank lenders have started asking diligence questions on these subjects, to meet their KYCC obligations.


These types of regulatory obligations are expanding rapidly. In 2019, for the third year in a row, the US Government blacklisted more entities than it had in any previous year, adding an average of 1,000 names each year—more than twice the annual average under either President Barack Obama or President George W. Bush. Companies would be wise to get the tools in place to manage these risks.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/leadership-perspective/the-evolving-financial-crime-regulatory-landscape-nwid-297.html